Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 20 opinions in the last 12 months.
McKesson Corp (MCK) is recognized as a significant player in the healthcare distribution sector, boasting strong market share and growth potential driven by demographic trends such as an aging population. Various experts highlight its role as a distributor of both branded and generic drugs, noting that it stands to benefit from the rising demand for pharmaceuticals, particularly weight-loss drugs. The company is generally viewed as a steady performer, trading at reasonable price-to-earnings (PE) ratios relative to its growth rates, which are characterized as healthy. Some analysts express concerns about the low margins in drug distribution and potential headwinds related to US healthcare dynamics, yet many believe MCK remains a solid investment with a compelling long-term outlook. Furthermore, the stock's ability to navigate challenges in the healthcare landscape positions it well for future growth.
Got stopped out when it gapped lower. You need only 20 positions to be diversified; you don't want to look like the index. If something isn't behaving as you expect, based on what you know, step aside and let things develop.
Broken down technically. Well below 200-day MA, which has rolled over. Has work to do, wouldn't put money here today. Others in the sector are doing better.
Frustrating backslide, but continues to believe in it. #1 player in a 3-player oligopoly. A need, not a want. Demographics of aging and morbidity trends are tailwinds. #9 position on the Fortune 500 is very secure. Pullback due to short-term headwinds of lower revenue in one small unit plus drug going off-patent. Rexall sale is a blessing, as it was a drag on performance.
Dividend has grown at 10% compound rate over 10 years, will continue. Trades at 14x earnings, likely to grow at 11-12% over next 3 years. Opportune entry point.
Just below 200-day MA. One of 3 members of an oligopoly, which together control 90% of the business out there. Steady earnings, decent valuation. 15-16x forward PE, steady 11-12% growth rate. Value here, even though it's a growth name. As people age, volume of drugs required can only increase, benefiting a name like this.
He also owns CAH.
McKesson Corp is a American stock, trading under the symbol MCK-N on the New York Stock Exchange (MCK). It is usually referred to as NYSE:MCK or MCK-N
In the last year, 6 stock analysts published opinions about MCK-N. 2 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for McKesson Corp.
McKesson Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for McKesson Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
6 stock analysts on Stockchase covered McKesson Corp In the last year. It is a trending stock that is worth watching.
On 2025-04-25, McKesson Corp (MCK-N) stock closed at a price of $695.
Is surprised the stock hasn't split. Is one of the strongest stocks out there and plays a valuable role in society, though Washington disagrees.